Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The uniQure N.V. (QURE) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, uniQure files current reports on Form 8‑K, annual reports on Form 10‑K, and quarterly reports on Form 10‑Q that describe its gene therapy business, clinical programs, financial condition, and material agreements. These filings document the company’s work in hemophilia B, Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe conditions.
For uniQure, Form 8‑K filings are particularly important. They include clinical and regulatory updates on AMT‑130 for Huntington’s disease, such as topline Phase I/II data, details of pivotal trial design, and feedback from pre‑Biologics License Application meetings with the U.S. Food and Drug Administration. Other 8‑K reports describe public offerings of ordinary shares and pre‑funded warrants, amendments to senior secured term loan facilities with Hercules Capital, and the establishment of at‑the‑market equity programs. Filings also reference the company’s role in the multi‑year clinical development of a gene therapy for hemophilia B and its licensing arrangements with CSL.
On this page, investors can review uniQure’s SEC documents to understand how it reports results of operations, research and development spending, direct financial obligations, and other events that may affect QURE stock. Stock Titan enhances access to these filings with AI‑powered summaries that highlight key points from lengthy reports, helping readers quickly identify major clinical milestones, regulatory decisions, financing terms, and risk disclosures. Real‑time updates from EDGAR, along with structured access to items such as 8‑K current reports and other registered offerings, support deeper analysis of uniQure’s evolving gene therapy portfolio and capital structure.
uniQure N.V. filed a Form 8-K to share that it has updated its corporate presentation for investors and other stakeholders. The company is providing the new presentation as Exhibit 99.1 under a Regulation FD disclosure, meaning it is being broadly shared to keep the market informed. The presentation is also available on uniQure’s investor relations website, although the website itself and its contents are not part of this report. The company states that the information in this item and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced.
uniQure N.V. director Jack Kaye reported exercising stock options and selling shares of the company on January 9, 2026. He exercised a stock option to buy 6,390 Ordinary Shares at an exercise price of $19.39 per share, then sold the same 6,390 Ordinary Shares at a weighted average price of $27.28 per share under transaction code "S".
These trades were carried out under a pre-arranged Rule 10b5-1 sales plan adopted on June 16, 2025, as described in the footnotes. After the reported transactions, Kaye directly owned 20,439 Ordinary Shares of uniQure N.V.
uniQure has a planned sale of ordinary shares under Rule 144. A person identified as Robert Gut filed to sell 25,613 ordinary shares through Citigroup Global Markets on the NASDAQ, with an aggregate market value of $676,695.00. The filing notes that there were 62,291,663 ordinary shares outstanding at the time, providing context for the sale size.
The shares to be sold include stock acquired on January 12, 2026 through a stock option exercise and sale pursuant to a Rule 10b5-1 trading plan, as well as vested share awards originally received in 2021 and 2022 as compensation from uniQure entities. The notice also discloses that Gut sold 31,434 ordinary shares on November 6, 2025 for gross proceeds of $856,881.00, as part of the required three-month sale history.
uniQure insider plans stock sale under Rule 144
A holder of uniQure N.V. ordinary shares filed a notice of proposed sale under Rule 144 for 6,390 ordinary shares, to be handled through Citigroup Global Markets, Inc. on the NASDAQ exchange. The filing lists an aggregate market value of $174,330.00 for these shares and notes that 62,291,663 ordinary shares were outstanding. The shares are described as acquired through a stock options exercise and sale pursuant to a Rule 10b5-1 trading plan, with cash as the form of payment. The notice also reports that Jack Kaye sold 38,810 ordinary shares during the past three months for $1,177,517.00 in gross proceeds.
uniQure N.V. filed a current report describing a communication milestone with U.S. regulators. On January 9, 2026, the company announced via press release that a Type A meeting with the U.S. Food and Drug Administration has been scheduled. This type of meeting is typically used to discuss important regulatory issues for a product or development program. The press release with further details is included as Exhibit 99.1 and is treated as information that is furnished, not filed, under securities law.
uniQure N.V. (QURE) disclosed insider transactions by a director on a Form 4 dated 11/06/2025. The reporting person exercised stock options for 15,840 ordinary shares at an exercise price of $4.57 (code M), then reported two open-market sales (code S): 15,840 shares at a weighted average price of $27.22 and 15,594 shares at $27.30. Following these transactions, 40,145 shares were beneficially owned directly.
The transactions were effected under a Rule 10b5-1 plan adopted on July 8, 2025. The filing notes footnote adjustments to prior reported holdings, and states the first sale’s weighted average reflects multiple trades between $27.00 and $27.38. The option covered 15,840 underlying shares, vested in full on June 19, 2025, and carries an expiration date of 06/19/2034.
uniQure (QURE) filed its Q3 2025 10‑Q, reporting wider losses but a much stronger cash position. Total revenues were $3.7 million, up from $2.3 million a year ago, driven by license revenue. Net loss was $80.5 million, compared to $44.4 million, as R&D and SG&A expenses increased and royalty‑financing interest remained sizable.
Liquidity improved materially: cash and cash equivalents were $597.1 million as of September 30, 2025. The company completed follow‑on offerings in January/February and September, receiving net proceeds of $70.1 million, $10.4 million, and $323.7 million, respectively; September included pre‑funded warrants to purchase 0.5 million shares and a $30.7 million related liability at quarter‑end. Liability from the HEMGENIX royalty financing was $469.1 million.
Debt was refinanced under a Hercules facility maturing October 1, 2030, with $50.0 million drawn and up to $100.0 million more available upon a Biologics License Application (BLA) approval for AMT‑130 prior to June 15, 2027. The company reported positive AMT‑130 Phase I/II topline data; however, following an October pre‑BLA meeting, the FDA feedback indicates the external‑control data may not be adequate as primary evidence, making BLA timing unclear. Ordinary shares outstanding were 62,165,900 as of September 30, 2025.
uniQure N.V. (QURE) furnished a press release announcing financial results for the quarter ended September 30, 2025 and provided a corporate update. The release is included as Exhibit 99.1 to a Form 8-K dated November 10, 2025.
The company states the information furnished under Item 2.02, including Exhibit 99.1, is not deemed “filed” under the Exchange Act. uniQure’s ordinary shares trade on the Nasdaq Global Select Market under the symbol QURE.
uniQure N.V. (QURE) disclosed that a director executed option exercises and same‑day sales on 11/04/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.
The director exercised 10,000 options at $7.37, 11,000 at $5.37, and 17,810 at $14.08, then sold equivalent ordinary shares at weighted average prices of $30.36, $30.34, and $30.33, respectively. Following these transactions, the director beneficially owned 20,439 ordinary shares, held directly.
uniQure reported a regulatory setback for AMT-130, its investigational gene therapy for Huntington’s disease. Following a pre-BLA meeting, the company believes the FDA currently no longer agrees that data from its Phase I/II studies, analyzed against an external control per prespecified protocols and statistical plans, may be adequate as primary evidence for a BLA.
As a result, the timing of the BLA submission for AMT-130 is now unclear. The update was announced on November 3, 2025 via a press release furnished as an exhibit. The disclosure highlights risks common to early-stage gene therapies, including evolving regulatory views on endpoints and comparators, and the potential need for additional clinical evidence.